Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Ultragenyx Pharmaceutical’s 10-Q, filed August 5, 2026.
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333233
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Total revenues | 214 | 167 | 350 | 306 |
| Operating expenses: | ||||
| Cost of sales | 34 | 23 | 64 | 52 |
| Research and development | 167 | 165 | 354 | 331 |
| Selling, general and administrative | 88 | 87 | 176 | 174 |
| Total operating expenses | 289 | 275 | 594 | 557 |
| Loss from operations | (75) | (108) | (244) | (251) |
| Interest income | 5 | 6 | 11 | 13 |
Item 1. Financial Statements
FAQ
- What is Ultragenyx Pharmaceutical's R&D?
- Ultragenyx Pharmaceutical (RARE) reported R&D of $167M in Q2 2026.
- How has Ultragenyx Pharmaceutical's R&D changed year-over-year?
- Ultragenyx Pharmaceutical's R&D increased by 1.2% year-over-year, from $165M to $167M.
- What is the long-term trend for Ultragenyx Pharmaceutical's R&D?
- Over 4 years (2021 to 2025), Ultragenyx Pharmaceutical's R&D has grown at a 10.8% compound annual growth rate (CAGR), from $497.15M to $750.49M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Ultragenyx Pharmaceutical's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude